← All trials
NCT04844905
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2021
- Primary completion
- Mar 31, 2023
- Completion date
- Aug 31, 2023
- First posted
- Apr 14, 2021
- Last posted
- Apr 14, 2021
- Enrollment
- 24000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of LondonLead sponsor
- Medical Research Council, The GambiaCollaborator
- University of LondonOverall official - principal investigator
- Bandim Health ProjectCollaborator
- Government of Guinea-BissauCollaborator
- Government of Guinea-BissauCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.